FUJIFILM Group, a publicly owned company founded in 1934 and headquartered in Japan, employs approximately 72,260 people. In 2023, the company reported revenues exceeding $1 billion. Its diverse business portfolio includes healthcare (medical systems, bio-CDMO, and life science solutions), electronics (semiconductor, display, and other materials), business innovation (business, office, and graphic communications solutions), and imaging (consumer and professional products).
On July 7, 2025, Fujifilm Pharmaceuticals USA Inc. announced that the FDA granted orphan drug designation to FF-10832, a liposomal formulation of gemcitabine, for treating biliary tract cancer. On June 17, 2025, ClassOne Technology announced receiving a repeat order from Fujifilm Dimatix for a Solstice single-wafer processing system. This system will be used for volume gold electroplating of inkjet printheads in commercial and industrial applications.
Subscribe for full access to FUJIFILM Group's products in full detail
Subscribe for full access to FUJIFILM Group's revenue in full detail
Subscribe for full access to FUJIFILM Group's products in full detail 
